Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 versus HyQvia pharmacokinetics crossover study in primary immunodeficiency diseases
2022-502095-23-01Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of TAK-881 in Immunogenetic disorder and Primary antibody deficiency (PAD) (3 arms), sponsored by Takeda. Primary endpoint: AUC0-τ,ss based on total IgG levels. Started Aug 2024; status: completed.
02
Drugs
TAK-881
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)
Beyond the preview
Go deeper on 2022-502095-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502095-23-01.